<DOC>
	<DOCNO>NCT00989352</DOCNO>
	<brief_summary>The purpose study determine whether combined chemotherapy [ rituximab plus high dosage methotrexate , lomustine , procarbazine ] follow maintenance therapy procarbazine effective treatment cerebral Non Hodgkin lymphoma [ PCNSL ] patient &gt; 65 year .</brief_summary>
	<brief_title>Methotrexate-based Chemo-immunotherapy Followed Maintenance Therapy Patients &gt; 65 Years With Central Nervous System ( CNS ) -Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<criteria>first diagnosis PCNSL , histologically confirm age &gt; 65 year write sign date informed consent legal representative possible patient manifestation lymphoma outside CNS seropositive HIV severe pulmonary , cardiac , hepatic , renal impairment uncontrolled infection neutrophil count &lt; 1.500/µl , platelet count &lt; 100.000/µl pulmonary disease IVC &lt; 55 % , DLCO &lt; 40 % cardiac ejection fraction &lt; 50 % , uncontrolled malign arrhythmia creatinine &gt; 1,5 mg % creatinineclearance &lt; 50ml/min bilirubin &gt; 2mg/dl ascites pleural effusion ( &gt; 500ml ) know hypersensitivity methotrexate , lomustine , procarbazine , rituximab , leukovorin , dexamethasone participation another clinical trial within last 30 day prior begin parallel study know current drug alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>PCNSL</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Lomustine</keyword>
	<keyword>Procarbazine</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Elderly</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>